Regenxbio Inc
RGNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$384.11M
Close$
$25.02
236.7% upside
Current Fair Value
236.7% upsideUndervalued by 236.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $384.11 Million |
|---|---|
| Enterprise Value | $495.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.76 |
| Beta | 0.93 |
| Outstanding Shares | 52,820,000 |
Return
| Return on Equity | -273.72% |
|---|---|
| Return on Assets | -50.81% |
| Return on Invested Capital | -53.59% |
Valuation & Multiples
| P/E Ratio | -1.96 |
|---|---|
| PEG | 1.48 |
| Price to Sales | 2.48 |
| Price to Book Ratio | 7.43 |
| Enterprise Value to Revenue | 2.84 |
| Enterprise Value to EBIT | -3.04 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$97.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$15.86 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3293▼ 34.85% |
|---|---|
| Total Calls | 523,000▲ 26.05% |
| Total Puts | 172,200▼ 38.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 81.23%▼ 0.01% |
|---|---|
| Total Invested | $509.36M▲ 43.43% |
| Investors Holding | 177▼ 12.00% |
ESG Score
No data
About Regenxbio Inc
CEO: Kenneth Mills